Levocetirizine/Montelukast- Qrono

Drug Profile

Levocetirizine/Montelukast- Qrono

Alternative Names: QR 215

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Qrono
  • Class Acetates; Antiallergics; Antiasthmatics; Nonsedating antihistamines; Piperazines; Quinolines; Quinolones
  • Mechanism of Action Histamine H1 receptor antagonists; Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 16 Aug 2017 Chemical structure information added
  • 04 Aug 2017 Levocetirizine/Montelukast- Qrono is available for licensing as of 04 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)
  • 04 Aug 2017 Early research in Undefined indication in USA (Parenteral) (Qrono pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top